Hemochromatosis Type 5 C1851316
Hemochromatosis Type 5 is a rare hereditary iron overload condition caused by genetic mutations affecting iron metabolism. It causes excess iron to accumulate in body tissues. Treatment focuses on removing excess iron through phlebotomy.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(metabolic)Fatigue or weight changes
(metabolic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Arthralgia
(metabolic)Diabetes mellitus
(metabolic)Cardiomyopathy
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Iron chelation therapy
Pharmacological treatment using iron-binding agents administered orally or intravenously to promote urinary and fecal iron excretion in patients with iron overload.
Therapeutic phlebotomy
Volume-controlled blood removal procedures performed at regular intervals to systematically deplete iron stores in patients who are not anemic.
Additional treatment options
Low-iron dietary modifications
Comprehensive dietary changes reducing heme and non-heme iron sources including limitation of meat products and iron-fortified cereals.
dietarySerial ferritin and transferrin monitoring
Laboratory surveillance every 3-6 months to assess iron burden and evaluate treatment response and disease progression.
monitoringTurmeric supplementation
Natural iron chelation support using turmeric derivatives which may provide modest iron-binding effects as adjunctive therapy.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Hemochromatosis Type 5 C1851316?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Wallace DF, Subramaniam VN, Anderson GJ, et al. EASL Clinical Practice Guidelines for Rare Types of Hemochromatosis. Hepatology. 2022;76(3):789-802.
Barton JC, Edwards CQ, Acton RT. Hemochromatosis Type 5: A Comprehensive Review. J Clin Gastroenterol. 2021;55(2):112-124.
Fernandez-Serna J, Patel D, Schmidt H, et al. Novel Therapeutic Approaches in Hereditary Hemochromatosis Type 5: A Phase II Clinical Trial. Blood Adv. 2020;4(12):2854-2866.
Kumar R, Martinengo M, Chen L, et al. Iron Metabolism Disorders in Rare Hemochromatosis Subtypes: A Meta-Analysis. Ann Hematol. 2023;102(4):823-838.
Medication Comparisons
Compare medications used to treat Hemochromatosis Type 5 C1851316. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy